Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus SEPTRA GRAPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus SEPTRA GRAPE.
CORDRAN N vs SEPTRA GRAPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Septra Grape (trimethoprim/sulfamethoxazole) inhibits bacterial folic acid synthesis via sequential blockade: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
160 mg trimethoprim / 800 mg sulfamethoxazole (1 double-strength tablet) orally every 12 hours.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Trimethoprim: 8-10 hours (renal impairment >24h). Sulfamethoxazole: 10-13 hours (acetylation phenotype; prolonged in renal impairment). Clinical: Dosing interval generally 12h; adjust CrCl <30 mL/min.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Renal: 50-70% unchanged (trimethoprim), 30-50% as N-acetyl metabolite; sulfamethoxazole: 70-80% as metabolites, 20-30% unchanged; biliary excretion minimal (<5% total).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic